Grifols (NASDAQ:GRFS) Raised to Strong-Buy at Wall Street Zen

Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.

Separately, JPMorgan Chase & Co. raised their target price on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research note on Tuesday.

Grifols Trading Up 0.8%

Shares of GRFS stock opened at $8.77 on Friday. The stock has a market cap of $6.03 billion, a price-to-earnings ratio of 7.50, a PEG ratio of 0.31 and a beta of 0.53. The stock has a 50-day moving average of $7.90 and a 200-day moving average of $7.60. The company has a current ratio of 2.60, a quick ratio of 0.97 and a debt-to-equity ratio of 1.13. Grifols has a 1-year low of $5.79 and a 1-year high of $9.96.

Institutional Investors Weigh In On Grifols

A number of hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its stake in Grifols by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after acquiring an additional 1,657 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Grifols by 4.6% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 46,078 shares of the biotechnology company's stock valued at $328,000 after purchasing an additional 2,026 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Grifols by 14.9% during the first quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after acquiring an additional 3,399 shares during the period. Versant Capital Management Inc bought a new stake in Grifols during the first quarter worth $28,000. Finally, HighTower Advisors LLC lifted its holdings in Grifols by 28.3% during the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock worth $133,000 after acquiring an additional 3,936 shares during the period.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.